Fig. 3From: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyChange in MIDAS scores at 12 weeks by age. MIDAS, Migraine Disability Assessment; LSM, least-squares mean; SE, standard error. aP = 0.021 vs placebo. bP < 0.001 vs placeboBack to article page